Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: A prospective observational study

Clinical and Experimental Immunology

Volumn 180, Issue 1, 2015, Pages 11-18

  Trouvin, A P ^a   Jacquot, S ^a,b   Grigioni, S ^a   Curis, E ^c   Dedreux, I ^a,b   Roucheux, A ^a,b   Boulard, H ^a   Vittecoq, O ^a,b   Le Loet X ^a   Boyer, O ^a,b   Goeb V ^d,e  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

B lymphocyte depletion; Rheumatoid arthritis; Rituximab

Indexed keywords

CD19 ANTIGEN; CORTICOSTEROID; METHOTREXATE; RITUXIMAB; ANTIRHEUMATIC AGENT; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG MONITORING; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; LOW DRUG DOSE; LYMPHOCYTE TYPING; MALE; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; FOLLOW UP; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MIDDLE AGED; PHYSIOLOGIC MONITORING; PROCEDURES;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; RITUXIMAB;

EID: 84924333657     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12481     Document Type: Article

References (31)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
2. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112:1570-1580.
3. Marie-Cardine A, Divay F, Dutot I etal. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol 2008; 127:14-25.
4. Edwards JC, Szczepanski L, Szechinski J etal. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
5. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61:883-888.
6. Cambridge G, Leandro MJ, Edwards JC etal. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146-2154.
7. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54:2377-2386.
8. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54:723-732.
9. Nakou M, Katsikas G, Sidiropoulos P etal. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009; 11:R131.
10. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11:R123.
11. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58:1566-1575.
12. Buch MH, Smolen JS, Betteridge N etal. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:909-920.
13. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613-620.
14. Carson KR, Evens AM, Richey EA etal. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood 2009; 113:4834-4840.
15. van Vollenhoven RF, Emery P, Bingham CO 3rd etal. Long-term safety of rituximab in rheumatoid arthritis: 9·5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72:1496-1502.
16. Smolen JS, Aletaha D, Bijlsma JW etal. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631-637.
17. Aletaha D, Neogi T, Silman AJ etal. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580-1588.
18. Anolik JH, Friedberg JW, Zheng B etal. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122:139-145.
19. Vital EM, Dass S, Rawstron AC etal. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62:1273-1279.
20. Chatzidionysiou K, Lie E, Nasonov E etal. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70:1575-1580.
21. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, British Society for Rheumatology Biologics Register. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012; 39:240-246.
22. Quartuccio L, Fabris M, Salvin S etal. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxf) 2009; 48:1557-1559.
23. Isaacs JD, Cohen SB, Emery P etal. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72:329-336.
24. Narvaez J, Diaz-Torne C, Ruiz JM etal. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 2011; 29:991-997.
25. Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 2010; 9:801-803.
26. Solau-Gervais E, Prudhomme C, Philippe P etal. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012; 79:281-284.
27. Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken) 2012; 65:648-652.
28. Sellam J, Hendel-Chavez H, Rouanet S etal. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63:933-938.
29. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 2013; 43:9-17.
30. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58:2993-2999.
31. Vital EM, Rawstron AC, Dass S etal. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011; 63:603-608.